InvestorsHub Logo
Followers 505
Posts 6242
Boards Moderated 0
Alias Born 09/20/2006

Re: Investor100 post# 487

Wednesday, 01/29/2014 6:02:48 PM

Wednesday, January 29, 2014 6:02:48 PM

Post# of 689
HZNP @ Stockcharts

While most stocks are getting hammered this one is a winner..+18% and making $$$$

Solid volume at 9M shares and solid news taking this one much higher-bank on it!

7:33 am Horizon Pharma sees Q4 revs of $31.9-32.4 mln vs $27.4 mln CIQ est; provides VIMOVO update (HZNP) : Co provides preliminary revenues for the fourth quarter and fiscal year ended December 31, 2013.

For the fourth quarter of 2013, Horizon expects total net revenues of $31.9-32.4 mln vs $27.4 mln CIQ est.
According to Source Healthcare Analytics, total prescriptions for DUEXIS increased 13% in the fourth quarter of 2013 to 63,947 versus 56,673 in the third quarter of 2013.
Approximately 95% of commercially insured patients taking DUEXIS have a co-pay of twenty dollars or less.
According to SHA, total prescriptions for RAYOS increased 18% in the fourth quarter of 2013 to 2,973 versus 2,530 in the third quarter of 2013.
Approximately 95% of commercially insured patients taking RAYOS have a co-pay of less than twenty dollars.
Preliminary unaudited cash and cash equivalents at December 31, 2013 were ~$80.5 million.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.